By
Aaron Nicodemus2023-07-18T21:06:00
A federal judge ruled the digital asset token XRP does not intrinsically possess the characteristics of a security that must be registered with the Securities and Exchange Commission (SEC), a blow to the agency’s argument regarding the regulation of digital assets.
But experts believe the decision has not cleared the uncertainty that remains around the regulation of digital assets.
On Thursday, U.S. District Court Judge Analisa Torres ruled roughly half of the sale of approximately $1.3 billion worth of XRP by issuer Ripple Labs from 2012-20 did not violate securities law. She allowed the SEC to continue to pursue its allegation the sale of $728 million of XRP during that same period did violate the law.
2024-01-22T18:08:00Z By Aaron Nicodemus
The Securities and Exchange Commission’s approval of spot bitcoin exchange-traded funds will provide investors with the same access to bitcoin, bought for cash on the spot market, as they currently have to other investments—for better or worse.
2023-09-08T18:31:00Z By Aaron Nicodemus
Commissioner Caroline Pham of the Commodity Futures Trading Commission proposed the agency develop a regulatory pilot program for digital asset markets where new initiatives could be introduced and refined.
2023-08-18T14:01:00Z By Kyle Brasseur
The Securities and Exchange Commission’s two Republican commissioners dissented from an agency order against transfer agent DST Asset Manager Solutions they deemed to be an example of regulation by enforcement.
2025-12-10T15:30:00Z By Neil Hodge
For the past decade, Europe has led in creating strong but flexible rules for data use and safe AI development. The EU’s new plans to simplify key data privacy and AI governance measures have received a mixed response.
2025-12-05T19:25:00Z By Oscar Gonzalez
The U.S. Securities and Exchange Commission’s (SEC) Division of Examinations released its 2026 examination priorities, which give companies a roadmap of areas of heightened risk and regulatory focus for next year.
2025-12-04T22:15:00Z By Ruth Prickett
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Site powered by Webvision Cloud